A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency.
Aoki, M., Hayashi, H., Rao, K.V., Das, D., Higashi-Kuwata, N., Bulut, H., Aoki-Ogata, H., Takamatsu, Y., Yedidi, R.S., Davis, D.A., Hattori, S.I., Nishida, N., Hasegawa, K., Takamune, N., Nyalapatla, P.R., Osswald, H.L., Jono, H., Saito, H., Yarchoan, R., Misumi, S., Ghosh, A.K., Mitsuya, H.(2017) Elife 6
- PubMed: 29039736 
- DOI: 10.7554/eLife.28020
- Primary Citation of Related Structures:  
5TYS, 5TYR - PubMed Abstract: 
Antiretroviral therapy for HIV-1 infection/AIDS has significantly extended the life expectancy of HIV-1-infected individuals and reduced HIV-1 transmission at very high rates. However, certain individuals who initially achieve viral suppression to un ...